Chemicals · NSE/BSE: JUBLINGREA
Jubilant Ingrevia Limited
Specialty Chemicals
Market Cap ₹0.10L Cr
Verdict: Average
Quality Scores
Multi-Bagger
74/100
Compounder Quality
72/100
Management Credibility
78/100
Governance
85/100
Cash Flow Quality
88/100
AI Summary
Jubilant Ingrevia, spun off from Jubilant Life Sciences, is a vertically integrated specialty chemicals player with leadership in Pyridine, Vitamin B3, and Acetic Anhydride. The company serves global giants in pharma and agrochemicals, leveraging a low-cost manufacturing base. While the legacy business is 40 years old, as a standalone entity since 2021, it has faced significant margin compression from cyclical highs. Revenue has stagnated around ₹4,100-4,700 Cr, reflecting volatility in commodity chemical prices despite growth in specialty segments. The investment thesis hinges on a…
Top Opportunities
- Global leadership in Pyridine + Beta and Vitamin B3
- Strong client list including 15 of top 20 Global Pharma
- Reduction in Working Capital Days from 29.4 to 22.0
Top Risks
- Declining Operating margins (17% to 10%)
- Promoter holding decreased by 6.25%
- Low ROE of 8.48% over the last 3 years
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.